Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) EBT Margin (2022 - 2025)

Historic EBT Margin for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to 93.43%.

  • TriSalus Life Sciences' EBT Margin fell 607400.0% to 93.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 98.43%, marking a year-over-year increase of 1082100.0%. This contributed to the annual value of 102.07% for FY2024, which is 2185800.0% up from last year.
  • Latest data reveals that TriSalus Life Sciences reported EBT Margin of 93.43% as of Q3 2025, which was down 607400.0% from 73.94% recorded in Q2 2025.
  • In the past 5 years, TriSalus Life Sciences' EBT Margin registered a high of 27.44% during Q3 2023, and its lowest value of 698.57% during Q4 2022.
  • For the 4-year period, TriSalus Life Sciences' EBT Margin averaged around 218.0%, with its median value being 122.37% (2024).
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 5005600bps in 2024, then tumbled by -607400bps in 2025.
  • TriSalus Life Sciences' EBT Margin (Quarter) stood at 698.57% in 2022, then grew by 11bps to 622.93% in 2023, then soared by 80bps to 122.37% in 2024, then increased by 24bps to 93.43% in 2025.
  • Its EBT Margin was 93.43% in Q3 2025, compared to 73.94% in Q2 2025 and 113.12% in Q1 2025.